DMF5 recognizes the 27–35 nonameric and 26–35 decameric peptide epitopes from the MART-1 melanoma antigen presented by the class I MHC protein HLA-A*0201 (HLA-A2), and was the second TCR to be used in clinical trials of genetically engineered T cells [5]. The gene discussed is MLANA; the disease is melanoma.